Invizius Treats First Patients in First-In-Human Phase 1 Clinical Study of Lead Dialysis Product H-Guard®
- First patients treated with H-Guard® at the National Institute for Health and Care Research Manchester Clinical Research Facility
- MHRA approves continuation of Invizius’s first-in-human clinical study following a prearranged two-patient safety and performance review
- Study is investigating safety and tolerability of H-Guard®, a second generation complement regulator, to address serious immune system-driven complications of dialysis
Glasgow, Scotland, 7 February 2024 – Invizius Limited (“Invizius”), a biotechnology company developing breakthrough treatments for patients on dialysis, is pleased to announce that the first two patients have been treated at the National Institute for Health and Care Research (NIHR) Manchester Clinical Research Facility (CRF) with lead product, H-Guard® Priming Solution, in the Company’s first-in-human Phase 1 clinical study.
